- Today, we revisit Sangamo Therapeutics, Inc., which has attracted ~$780 million in upfront payments and investments for its genomic medicines’ platforms.
- Despite the all the attention, it has only one late-stage candidate, SB-525 for hemophilia A, which is being advanced through the clinic by Pfizer.
- With more collaborations than assets in the clinic and $665 million of cash as of June 30, 2020, Sangamo looks like a covered call candidate.
- A full investment analysis is provided in the paragraphs below.
For further details see:
Sizing Up Sangamo Therapeutics